期刊文献+

携带中国株HIV-1 gp120基因的重组腺病毒的构建及其感染巨噬细胞的形态学研究 被引量:2

Morphological study of macrophages infected with constructed recombinant adenovirus carrying gp120gene of Chinese HIV-1 strain
在线阅读 下载PDF
导出
摘要 目的:构建携带中国株HIV-1 gp120基因并可感染小鼠骨髓来源巨噬细胞(BMM)的重组腺病毒。方法:利用AdMax腺病毒构建系统,以双质粒共转染人胚肾转化细胞293Ad5+细胞,完成重组腺病毒载体包装,并进一步扩增和纯化。通过ELISA测定gp120的蛋白产量,以确认目的基因重组与表达成功。以Karber法对病毒进行TCID50滴度测定,利用BMM进行感染复数(MOI)流式细胞术测定,并利用荧光显微镜观察细胞活化形态。结果:成功构建AdMax-HIV-1 gp120(简称Ad-gp120)及其对照病毒(Ad-GFP),其滴度分别为108.3和108.1TCID50/mL。这些病毒可感染BMM,MOI测定结果表明2种重组腺病毒感染BMM和293Ad5+细胞的能力接近,验证了上述TCID50滴度结果。Ad-gp120可在293Ad5+细胞中表达gp120蛋白,并可感染和诱导BMM相关形态改变。结论:成功构建Ad-gp120,其感染可致BMM出现形态发生改变。 AIM: To construct a recombinant adenovirus carrying gp120 gene of Chinese HIV-1 strain,which can infect mouse bone marrow-derived macrophages (BMM). METHODS: Co-transfection of shuttle and backbone plasmids of AdMax system into 293Ad5+ cells was performed, followed by viral packaging, propagation and purification. These viruses were subject to Karber TCID50 titration. The expression of gp120 protein in 293Ad5+ cells was determined by ELISA. The viral titration was validated by a multiplicity of infection (MOI) test with BMM. RESULTS: The titers of the outcome viruses, including AdMax-HIV-1 gp120 (Ad-gp120) and its vector control Ad-GFP, were 108.3 and 108.1 TCID50/mL, respectively. Both recombinant adenoviruses infected BMM with similar capacity of 293Ad5+ cell infection, which validated the TCID50 titration.The gp120 protein was positive in 293Ad5+ cell lysates. BMM activation was observed morphologically after Ad-gp120 infection as compared with Ad-GFP-infected cells. CONCLUSION: Functional adenovirus containing HIV-1 gp120 of prevalent strains in China was successfully constructed. Infection of Ad-gp120 causes BMM activation.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2012年第6期1034-1038,共5页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.81000516) 教育部博士点基金资助项目(No.20104401120008) 中央高校基本科研业务费专项资金资助项目(No.21610602)
关键词 重组腺病毒 HIV包膜蛋白质gp120 骨髓来源巨噬细胞 Recombinant adenovirus HIV envelope protein gp120 Bone marrow-derived macrophages
  • 相关文献

参考文献16

  • 1Wang L,Wang N. The 2007 estimates for people at risk for and living with HIV in China:progress and challenges[J].Journal of Acquired Immune Deficiency Syndromes,2009,(04):414-418.
  • 2Hutter G,Nowak D,Mossner M. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation[J].New England Journal of Medicine,2009,(07):692-698.
  • 3Carter CC,Onafuwa-Nuga A,McNamara LA. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs[J].Nature Medicine,2010,(04):446-451.
  • 4Llewellyn N,Zioni R,Zhu H. Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy:genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy[J].Journal of Leukocyte Biology,2006,(05):1118-1126.
  • 5Valcour VG,Shiramizu BT,Shikuma CM. HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications[J].Journal of Leukocyte Biology,2010,(04):621-626.
  • 6Achenbach CJ,Cole SR,Kitahata MM. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy[J].Aids,2011,(05):691-700.
  • 7Jiang W,Jin N,Cui S. Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector[J].Journal of Virological Methods,2006,(1-2):1-7.
  • 8Hamilton MA,Russo RC,Thurston RV. Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays[J].Environmental Science and Technology,1977,(07):714-719.
  • 9Moulard M,Phogat SK,Shu Y. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes[J].Proceedings of the National Academy of Sciences(USA),2002,(10):6913-6918.
  • 10Gartner S. HIV infection and dementia[J].Science,2000,(5453):602-604.

二级参考文献11

  • 1Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor,T-bet,directs Th1 lineage commitment[J]. Cell, 2000, 100(6): 655-669.
  • 2Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of Th1 cells before IL-12-dependent selection[J]. Science, 2001, 292(5523): 1907-1910.
  • 3Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of T-bet in Th1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells[J]. Science, 2002, 295(5553): 338-342.
  • 4Kakumu S, Ito S, Ishikawa T, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection[J]. J Gastroenterol Hepatol, 2000, 15(4): 431-436.
  • 5Nishimura T, Nakui M, Sato M, et al. The critical role of Th 1-dominant immunity in tumor immunology[J]. Cancer Chemother Pharmacol, 2000, 46(Suppl): S52-S61.
  • 6He TC, Zhou S, DsCosta LT, et al. A simplified system for generating recombinant adenoviruses[J]. Proc Natl Acad Sci USA, 1998, 95(5): 2509-2521.
  • 7Chen Z, Ahonen M, Hamalainen H, et al. High-efficiency gene transfer to primary T lymphocytes by recombinant adenovirus vectors[J]. J Immunol Method, 2002, 260 (1): 79-89.
  • 8Horvath J, Weber JM. Nonpermissivity of human peripheral blood lymphocytes to adenovirus type 2 infection[J]. J Virol, 1988, 62(1): 341-345.
  • 9Leon R, Hedlund T, Meech S, et al. Adenoviral-mediated gene transfer in lymphocytes[J]. Proc Natl Acad Sci USA, 1998, 95(22): 13159-13164.
  • 10项兆英.一种新的幽门螺杆菌分类法──根据幽门螺杆菌毒力因子CagA和VacA的表达[J].中华消化杂志,1995,15(S1):5-8. 被引量:91

共引文献8

同被引文献13

  • 1王德利,阮狄克,李海峰,马巍,刘碧波,杨敏杰.骨形成蛋白2重组腺病毒的构建与鉴定[J].中华实验外科杂志,2004,21(6):737-738. 被引量:6
  • 2郜勇,杨述华,杨操,王瑞英,叶树楠.人血管内皮细胞生长因子重组腺病毒载体的构建、鉴定及在骨髓间充质干细胞的表达[J].中华实验外科杂志,2006,23(2):138-140. 被引量:7
  • 3Ng P, Parks RJ, Cummings DT, et al. A high-efficiency Cre/lox Phasedsystem for construction of adenoviral vectors[J]. Hum Gene Ther, 1999,10(16):2667-2672.
  • 4St George JA. Gene therapy progress and prospects:adenoviral vectors[J]. Gene Ther,2003,10( 14) :1135-1141.
  • 5Xu HN, Huang WD, Cai Y, et al. HCCSl-armed, quad- ruple-regulated oncolytic adenovirus specific for liver canc- er as a cancer targeting gene-viro-therapy strategy[ J ]. Mol Cancer, 2011, 10:133.
  • 6Zhu ZB, Rivera AA, Makhija SK, et al. Targeting lung cancer using an infectivity enhanced CXCR4-CRAd [ J]. Lung Cancer, 2007 ,55 (2) : 145-156.
  • 7Shien K, Tanaka N, Watanabe M, et al. Anti-cancer effects of REIC/Dkk-3-encoding adenoviral vector for the treatment of non-small cell lung cancer [ J ]. PLoS One, 2014, 9(2):e87900.
  • 8Kim KH, Dmitriev IP, Saddekni S, et al. A phase I clini- cal trial of Ad5/3-A24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer[ J]. Gynecol Oncol, 2013, 130(3) :518-524.
  • 9Choi JW, Lee JS, Kim SW, et al. Evolution of oncolytic adenovirus for cancer treatment[ J]. Adv Drug Deliv Rev, 2012, 64(8) :720-729.
  • 10Chu QD, Sun G, Pope M, et al. Virotherapy using a no- vel chimeric oncolytic adenovirus prolongs survival in a hu- man pancreatic cancer xenograft model [ J ]. Surgery, 2012, 152(3) :441-448.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部